Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 299-303

  Rein, Philipp ^a,b,c   Saely, Christoph H ^a,b,c   Silbernagel, Günther ^d   Vonbank, Alexander ^a,b,c   Mathies, Rainer ^b   Drexel, Heinz ^a,b,c,e   Baumgartner, Iris ^d  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b Academic Teaching Hospital Feldkirch   (Austria)

^c PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^d UNIVERSITY OF BERN   (Switzerland)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary artery disease; High density lipoprotein cholesterol; Inflammation; Metabolic syndrome; Peripheral artery disease

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CLAUDICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRASOUND; ANGIOGRAPHY; BLOOD; CYTOLOGY; ECHOGRAPHY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR;

AGED; ANGIOGRAPHY; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS;

EID: 84922527522     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.021     Document Type: Article

References (31)

1. Heslop C.L., Frohlich J.J., Hill J.S. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J.Am. Coll. Cardiol. 2010, 55:1102-1109.
2. Retterstol L., Eikvar L., Bohn M., et al. C-reactive protein predicts death in patients with previous premature myocardial infarction-a 10 year follow-up study. Atherosclerosis 2002, 160:433-440.
3. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N.Engl. J. Med. 2006, 355:2631-2639.
4. Brevetti G., Schiano V., Laurenzano E., et al. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur. Heart J. 2008, 29:224-230.
5. Criqui M.H., Ho L.A., Denenberg J.O., et al. Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. J.Vasc. Surg. 2010, 52:85-90.
6. Vidula H., Tian L., Liu K., et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann. Intern Med. 2008, 148:85-93.
7. Welten G.M., Schouten O., Hoeks S.E., et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J.Am. Coll. Cardiol. 2008, 51:1588-1596.
8. Santos A.C., Lopes C., Guimaraes J.T., et al. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int. J. Obes. (Lond) 2005, 29:1452-1456.
9. Ridker P.M., Wilson P.W., Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 2004, 109:2818-2825.
10. Conen D., Rexrode K.M., Creager M.A., et al. Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation 2009, 120:1041-1047.
11. Rein P., Saely C.H., Beer S., et al. Roles of the metabolic syndrome, HDL cholesterol, and coronary atherosclerosis in subclinical inflammation. Diabetes Care 2010, 33:1853-1855.
12. Scanlon P.J., Faxon D.P., Audet A.M., et al. ACC/AHA guidelines for coronary angiography. A report of the American college of cardiology/american heart association task force on practice guidelines (Committee on coronary angiography). Developed in collaboration with the society for cardiac angiography and interventions. J.Am. Coll. Cardiol. 1999, 33:1756-1824.
13. Saely C.H., Koch L., Schmid F., et al. Adult treatment panel III 2001 but not international diabetes federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006, 29:901-907.
14. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of Arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur. Heart J. 2013, 34:2159-2219.
15. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013, 36(Suppl.1):S67-S74.
16. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735-2752.
17. Saely C.H., Vonbank A., Rein P., et al. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin. Chim. Acta 2008, 397:82-86.
18. Bloemenkamp D.G., van den Bosch M.A., Mali W.P., et al. Novel risk factors for peripheral arterial disease in young women. Am. J. Med. 2002, 113:462-467.
19. Pradhan A.D., Rifai N., Ridker P.M. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002, 106:820-825.
20. Rizza S., Cardellini M., Martelli E., et al. Occult impaired glucose regulation in patients with atherosclerosis is associated to the number of affected vascular districts and inflammation. Atherosclerosis 2010, 212:316-320.
21. Shankar A., Li J., Nieto F.J., et al. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am. Heart J. 2007, 154:495-501.
22. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N.Engl. J. Med. 2008, 359:2195-2207.
23. Falk E. Pathogenesis of atherosclerosis. J.Am. Coll. Cardiol. 2006, 47:C7-C12.
24. Ross R. Atherosclerosis-an inflammatory disease. N.Engl. J. Med. 1999, 340:115-126.
25. Pellegatta F., Folli F., Ronchi P., et al. Deranged platelet calcium homeostasis in poorly controlled IDDM patients. Diabetes Care 1993, 16:178-183.
26. Vicari A.M., Monzani M.L., Pellegatta F., et al. Platelet calcium homeostasis is abnormal in patients with severe arteriosclerosis. Arterioscler. Thromb. 1994, 14:1420-1424.
27. Brevetti G., Giugliano G., Brevetti L., et al. Inflammation in peripheral artery disease. Circulation 2010, 122:1862-1875.
28. Wildman R.P., Muntner P., Chen J., et al. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am. J. Cardiol. 2005, 96:1579-1583.
29. Aboyans V., Criqui M.H., Denenberg J.O., et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006, 113:2623-2629.
30. Fisher E.A., Feig J.E., Hewing B., et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2813-2820.
31. McGillicuddy F.C., de la Llera M.M., Hinkle C.C., et al. Inflammation impairs reverse cholesterol transport invivo. Circulation 2009, 119:1135-1145.